Key Highlights
- Dr. Will Wei joins AusperBio as Head of CMC, SVP, bringing over two decades of biotech and pharmaceutical leadership.
- Wei’s appointment expected to enhance strategic execution and pipeline development for AusperBio’s oligonucleotide therapies.
- AusperBio continues to advance towards a functional cure for chronic hepatitis B, leveraging its proprietary Med-Oligo™ ASO platform.
Source: PR Newswire
Notable Quotes
- “We are excited to welcome Dr. Wei to AusperBio’s leadership team at this pivotal time for the company,” – Dr. Guofeng Cheng, Chief Executive Officer at AusperBio
- “Joining AusperBio is both an honor and an exciting opportunity…I’m excited to lead and collaborate with the outstanding team,” – Dr. Will Wei, Head of CMC, SVP at AusperBio
SoH's Take
Dr. Will Wei’s appointment as Head of CMC, SVP at AusperBio marks a significant step in the company’s journey towards revolutionizing the treatment of chronic hepatitis B. His extensive experience in drug development and successful leadership at global pharmaceutical companies is a valuable addition to the AusperBio team. This strategic move aligns with the company’s commitment to leverage its Med-Oligo™ ASO platform and targeted delivery technologies to address unmet medical needs. As the industry watches, AusperBio’s strengthened leadership and continued innovation promise to make strides in improving patient care and advancing towards a functional cure for CHB.
